Effects of monoamine oxidase inhibitor and cytochrome P450 2D6 status on 5-methoxy-N,N-dimethyltryptamine metabolism and pharmacokinetics
Authors:
- Chao WuCWChao Wu
- Xi-Ling JiangXJXi-Ling Jiang
- Ai-Ming YuAYAi-Ming Yu
- 1 July 2010
- journal article
- research article
- Published by Elsevier in Biochemical Pharmacology
- Vol. 80 (1) , 122-128
Abstract
No abstract availableKeywords
Funding Information
- National Institute On Drug Abuse, National Institutes of Health (NIH)
- National Center for Research Resources, NIH (S10RR014592)
This publication has 36 references indexed in Scilit:
- Effects of CYP2D6 status on harmaline metabolism, pharmacokinetics and pharmacodynamics, and a pharmacogenetics-based pharmacokinetic modelBiochemical Pharmacology, 2009
- Pinoline May be Used as a Probe for CYP2D6 ActivityDrug Metabolism and Disposition, 2009
- Expression and Functional Analysis of CYP2D6.24, CYP2D6.26, CYP2D6.27, and CYP2D7 IsozymesDrug Metabolism and Disposition, 2009
- Modification of the effects of 5-methoxy-N,N-dimethyltryptamine on exploratory behavior in rats by monoamine oxidase inhibitorsPsychopharmacology, 2008
- Indolealkylamines: Biotransformations and Potential Drug–Drug InteractionsThe AAPS Journal, 2008
- Contribution of Individual Cytochrome P450 Isozymes to the O-Demethylation of the Psychotropic β-Carboline Alkaloids Harmaline and HarmineThe Journal of Pharmacology and Experimental Therapeutics, 2003
- The Relative Contribution of Monoamine Oxidase and Cytochrome P450 Isozymes to the Metabolic Deamination of the Trace Amine TryptamineThe Journal of Pharmacology and Experimental Therapeutics, 2003
- Serotonin and HallucinogensNeuropsychopharmacology, 1999
- Serotonin and HallucinogensNeuropsychopharmacology, 1999
- Tissue distribution, metabolism and effects of bufotenine administered to ratsNeuropharmacology, 1995